LifeMD Inc (LFMD) fair value: what the stock is really worth
As of Oct 2, 2026: fair value of LifeMD Inc $0.58, price $2.74, upside -78.8%, quality 28 out of 100. Calculated from audited financials with 26 valuation models and 37 quality factors, updated daily.
Watch LifeMD Inc for free, get notified when fair value or trend changes. Plus fair value for all 35,000+ stocks, 14 days of Pro free, no card.Watch for freePro now: $1 first month
69 individual criteria per stock, every one traceableSee the method →
Price vs Fair Value
White line = price, green steps = our fair value per fiscal year, dashed = 300-day average. As of Oct 1, 2026.
How to read this chart
60‑month range $1.15 – $15.06 · fair‑value band $0.3800 – $0.7000 · the $2.74 price screens above the $0.5800 fair value. Green steps = our fair value per fiscal year (point-in-time, no hindsight). Dashed = 300-day average. As of Oct 1, 2026.
Follow LifeMD in your weekly email
Every Wednesday you see whether LifeMD is on track or worth a review, plus price against fair value. Free, up to 3 stocks.
We send you a confirmation link. Unsubscribe with one click.
LifeMD, Inc. operates as a direct-to-patient telehealth company, engages in the provision of patients access to virtual medical care and pharmacy services in the United States.
Show more
LifeMD, Inc. operates as a direct-to-patient telehealth company, engages in the provision of patients access to virtual medical care and pharmacy services in the United States. It offers telehealth platform comprising Rex MD, a men's telehealth platform that provides virtual diagnosis, treatment, and prescription medications for men's health conditions, including erectile dysfunction, premature ejaculation, hair loss, insomnia, weight loss, and performance anxiety; and ShapiroMD that provides virtual medical treatment, prescription medications, patented doctor formulated OTC products, topical compounded medications, and medical devices treating male and female hair loss. The company also provides LifeMD PC, a virtual primary care and telehealth service which is a provider for their primary care, urgent care, and chronic care needs; and offers virtual medical care, including on-demand consultations and treatment, prescription medications, diagnostics and imaging, wellness coaching, integration with in-home tools, and more. In addition, it offers GLP-1 for weight management and in-home health monitoring devices. The company was formerly known as Conversion Labs, Inc. and changed its name to LifeMD, Inc. in February 2021. LifeMD, Inc. was founded in 1994 and is headquartered in New York, New York.
Stock analysis
LifeMD Inc (LFMD) currently trades at $2.74, while our model-based Fair Value estimate is $0.5800, 78.8% below the price, so the stock looks overvalued today.
Show more
Valuation
Bull case: the Dividend Discount group reads highest at a median of $0.7100 per share, and 0 of the 3 models we run sit above the $2.74 price.
Bear case: the Asset-Based group reads lowest at $0.3200, and 3 of the 3 models stay below the price. Evidence for this calculation is low.
Scenario range: $0.3800 (bear) to $0.7000 (bull), the price of $2.74 sits above it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.
Quality & growth
The Quality Score stands at 28/100 (below-average quality), in the Healthcare sector.
Expensive Growth: The company is growing, but growth may require heavy reinvestment or weak cash conversion.
LifeMD Inc reported revenue of $194M in FY2025 versus $92.9M in FY2021, a compound +20.2%/yr. Reported net income was −$7.1M in FY2025.
Key figures
Market cap $131M · P/S ratio 0.73 · EPS (TTM) $−0.5300 · Dividend yield 2.2% · Net margin −3.7% · Return on equity −516% · Return on assets (EBIT) −67.2% · Operating margin −15.1%.
Competitive moat
Our AI-assisted moat analysis scores the competitive advantage at 42 out of 100 (low confidence).
What moves the price
The share trades about 61% below its 52-week high and 4% above its 52-week low, currently below its 200-day average.
For context, the median of 10 Healthcare peers we cover trades at 6% fair-value upside, at −79%, LFMD screens richer than that median.
Fair Value models
Bear $0.3800Fair Value $0.5800Bull $0.7000
Model ⓘEach model values the company its own way (discounted cash flow, earnings, assets, dividends). The fair value above is their evidence-weighted blend, not the output of a single model.Bear ⓘBear = the cautious scenario: the same model computed with conservative anchors (lower growth, margins and valuation multiples). Together with Bull it frames a plausible valuation range, not a price target.BaseBull ⓘBull = the optimistic scenario: the same model computed with favourable anchors (higher growth, margins and valuation multiples). Together with Bear it frames a plausible valuation range, not a price target. If a model's bull case is above four times its base value, the table shows that limit with a > sign (like the overall Bull above): beyond it no assumption holds.Evidence ⓘEvidence = how well-backed THIS model's estimate is for this stock (0–100): how complete and reliable its input data are, and how well the model fits the company. The final Fair Value is an evidence-weighted blend, so better-evidenced models count more. Green ≥70, amber 50–69, grey below 50.
Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card.52/100
The company is growing, but growth may require heavy reinvestment or weak cash conversion.
Revenue growth 1 year
−8.7%
Revenue growth 3 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+17.7%
Revenue growth 5 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+39.1%
Start year 2020 (pandemic). Over 10 years: +66.0% a year
Revenue growth 14 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+48.8%
’14
’15
’16
’17
’18
’19
’20
’21
’22
’23
’24
’25
Profit margin (trend) ⓘOperating margin then vs now, from reported annual statements. A falling margin after a boom year is the classic peak-earnings signal: the growth rate then leans on an inflated base.
−155.0% (2020) → −4.0% (2025)
What shareholders gained per year ⓘWe only publish this rate when it is defensible. Reason: fiscal 2025 is a loss year, no rate is defined from a loss
Price, fair value, quality and upside side by side.
Free, no sign-up
Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Health Information Services · 128 stocks
Beats the industry median on 2/10 measures
Overall it trails its industry peers.
Valuation
Quality Score28 · Bottom 25%
Fair Value upside−79.6% · Bottom 25%
Profitability
Return on assets−18.9% · Bottom 25%
Net margin (TTM)0.1% · Below median
Operating margin (TTM)−15.1% · Below median
Growth and dividend
Revenue growth−3.5% · Bottom 25%
Dividend yield (TTM)2.2% · Above median
Balance sheet
Debt / equity0.43× · Highest 25%
Valuation Multiplesvs Health Information Services median · lower = cheaper
P/B5.88× · Priciest 25%
P/S (TTM)0.71× · Cheapest 25%
Strength profile in five axes (Snowflake)
This stockSector peers
VALUE (fair-value potential)0· sector 0
FUTURE (revenue growth)0· sector 41
PAST (return on equity)0· sector 8
HEALTH (low debt)79· sector 98
DIVIDEND (yield)44· sector 44
VALUE 0: the price sits above our fair-value range.
For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.
Cite: Fair Value Calculator (2026). "LifeMD Inc Fair Value". https://www.fairvalue-calculator.com/stock/LFMD
Frequently asked questions
Is LifeMD Inc (LFMD) overvalued or undervalued?
As of Oct 1, 2026, our model estimates a fair value of $0.5800 versus a price of $2.74, about −79% upside (overvalued).
What is the fair value of LFMD?
Our model-based fair value for LifeMD Inc is $0.5800 (as of Oct 1, 2026), built from audited fundamentals. The current price: $2.74.
What is the quality score of LFMD?
LifeMD Inc has a Quality Score of 28/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for LifeMD Inc (LFMD)?
Our model-based price target is the fair value of $0.5800 (as of Oct 1, 2026) from 3 valuation models. Cautious scenario $0.3800, optimistic scenario $0.7000. It is a calculation from audited fundamentals, not an analyst target.
What is the LifeMD Inc stock forecast for 2026?
Our models put fair value at $0.5800, about −79% upside versus a price of $2.74 (overvalued). Cautious scenario $0.3800, optimistic scenario $0.7000. The calculation is refreshed regularly with new filings.
What is the revenue of LifeMD Inc (LFMD)?
LifeMD Inc reported trailing-twelve-month revenue of about $192M (latest available figure, as of Oct 1, 2026).
Does LifeMD Inc pay a dividend?
LifeMD Inc currently shows a dividend yield of about 2.22% relative to its recent price (as of Oct 1, 2026).
What is the intrinsic value of LifeMD Inc (LFMD)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For LifeMD Inc it is $0.5800 per share (as of Oct 1, 2026), against a price of $2.74. It is the blended result of 3 valuation models (cash flow, earnings, asset, dividend).
Is LifeMD Inc stock overvalued or undervalued in 2026?
As of Oct 1, 2026, LFMD trades above its calculated fair value: price $2.74, fair value $0.5800, a gap of about −79% (overvalued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of LFMD?
No. The price is what the market pays today ($2.74); the fair value is what the company's own numbers justify ($0.5800). For LifeMD Inc the two are $2.16 per share apart. That gap is exactly why we show both numbers side by side.
How much is LifeMD Inc worth?
The market values LifeMD Inc at about $131M (market capitalisation, as of Oct 1, 2026). Per share that is $2.74; our models calculate a fair value of $0.5800 per share.
What do the bullish and bearish scenarios say about LFMD?
Our models span a range for LifeMD Inc: cautious scenario $0.3800, base $0.5800, optimistic $0.7000 per share (as of Oct 1, 2026, price $2.74). The range comes from different growth and margin assumptions, not from analyst opinions.
How solid is the balance sheet of LifeMD Inc (LFMD)?
Balance-sheet figures for LifeMD Inc (as of Oct 1, 2026): debt of 0.43 per unit of equity. They feed the Quality Score of 28/100, which measures business quality independently of the share price.
How far is LFMD from its 52-week high?
LifeMD Inc trades at $2.74, about 61% below its 52-week high of $6.97 and 4% above the low of $2.64 (as of Oct 2, 2026). Distance from the high says nothing about value: that is what the fair value of $0.5800 is for.
Which stocks are comparable to LifeMD Inc?
From the same area (Healthcare) we also value Veeva Systems Inc, Pro Medicus Limited, BrightSpring Health Services, Inc, Hinge Health, Inc, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is LifeMD Inc stock attractive at the current price?
The data as of Oct 1, 2026: price $2.74, calculated fair value $0.5800 (−79%), Quality Score 28/100, from 3 models. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
How is the fair value of LFMD calculated?
We run LifeMD Inc through 3 models from four families: discounted cash flow, earnings models, asset and balance-sheet models, and dividend models. Every model gets the same audited fundamentals; the result is the weighted average of $0.5800, with the spread shown as a cautious and an optimistic scenario.
Is it still worth investing in stocks now?
The global stock market currently sits 14.5 % above its aggregate fair value. LifeMD Inc itself currently trades above fair value. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What is the share price of LifeMD Inc (LFMD)?
The closing price on Oct 2, 2026 was $2.74. Our model-based fair value is $0.5800, about −79% upside (overvalued). We carry closing prices from our data provider, not a live tick.
What should I pay attention to with LifeMD Inc right now?
The price sits above even our optimistic bull case ($0.7000). The favourable scenario is already priced in. Weak quality (28/100) and above fair value at the same time, the margin of safety is missing on both counts. The large gap to fair value rests on thin data (low evidence): fewer applicable models and a shorter history. Read it with extra caution. A fairly wide model range ($0.3800 to $0.7000) leaves room in how you read the outcome.
Key figures of LifeMD Inc
How large is the market capitalisation of LifeMD Inc (LFMD)?
The market capitalisation of LifeMD Inc is $131M. The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What is the P/S ratio of LifeMD Inc (LFMD)?
The price-to-sales ratio of LifeMD Inc is 0.73 (last twelve months). Price to sales: market value relative to yearly revenue. Useful when profit is thin or distorted.
What are the earnings per share of LifeMD Inc (LFMD)?
Earnings per share at LifeMD Inc are $−0.5300. Earnings per share over the last twelve months: total profit spread across every single share.
What is the dividend yield of LifeMD Inc (LFMD)?
The dividend yield of LifeMD Inc is 2.2%. Yearly dividend relative to the share price. 3% pays 3 per 100 invested. Below: how much of profit is used for it.
What is the net margin of LifeMD Inc (LFMD)?
The net margin of LifeMD Inc is −3.7% (fiscal year 2025). How much of every unit of revenue ends up as profit. 10% means 10 cents of profit per dollar of sales.
What is the return on equity of LifeMD Inc (LFMD)?
The return on equity (ROE) of LifeMD Inc is −516% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.
What is the EBIT return on assets of LifeMD Inc (LFMD)?
On an EBIT basis the return on assets of LifeMD Inc is −67.2% (avg 5y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
What is the operating margin of LifeMD Inc (LFMD)?
The operating margin of LifeMD Inc is −15.1% (last twelve months). Profit from the core business (before interest and taxes) relative to revenue.
How fast is revenue growing at LifeMD Inc (LFMD)?
Revenue at LifeMD Inc is growing −3.5% versus a year earlier (3y avg +17.7%). How much revenue grew versus a year earlier (YoY). The 3-year average next to it puts the single year in context.
How much free cash flow does LifeMD Inc (LFMD) generate?
The free cash flow of LifeMD Inc is −$1.2M (fiscal year 2025). The cash truly left after running and investing in the business, this is what pays dividends and buybacks.
How much net cash does LifeMD Inc (LFMD) hold?
LifeMD Inc holds more cash than debt, $30.5M net (fiscal year 2025). The company holds more cash than debt, a safety cushion.
Free · no account needed
Watch LifeMD Inc in the live analysis
One click puts LifeMD Inc on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 35,000+ stock screener. You can also try 14 days of Pro there, no card.
Thin data
Oct 1, 2026